tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us
Astellas Pharma Inc (JP:4503)
TSE/TYO:4503
4503
Astellas Pharma
Stock Analysis
Analyst Forecasts
Technical Analysis
Chart
Earnings
Dividends
Ownership
Similar Stocks
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Holding JP:4503?
Track your performance easily
Link Broker

Astellas Pharma (4503) Stock Price & Analysis

3 Followers

4503 Stock Chart & Stats

Advanced Chart >
Day’s Range¥0 - ¥0
52-Week Range¥1,426.00 - ¥1,839.50
Previous Close¥1,572
Volume14.54M
Average Volume (3M)5.89M
Market Cap
¥2.83T
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)51.4
Beta0.48
Next Earnings
Jan 30, 2025
EPS Estimate
¥18.49
Next Dividend Ex-Date
Mar 28, 2025
Dividend Yield4.73%
Share Statistics
EPS (TTM)30.60
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume5,889,931
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,950.55
Price Target Upside24.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7

Astellas Pharma News

Astellas Faces FDA Setback on IZERVAY Application
PremiumCompany Announcements
Astellas Faces FDA Setback on IZERVAY Application
8d ago
Astellas Pharma Faces Currency Losses in FY2024
PremiumCompany Announcements
Astellas Pharma Faces Currency Losses in FY2024
28d ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
30d ago
Astellas Pharma Withdraws EU Application for Key Drug
PremiumCompany Announcements
Astellas Pharma Withdraws EU Application for Key Drug
1M ago
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
PremiumCompany Announcements
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
1M ago
Astellas’ New Cancer Therapy Gains Japan Approval
PremiumCompany Announcements
Astellas’ New Cancer Therapy Gains Japan Approval
2M ago
Astellas Wins EU Approval for Advanced Cancer Drug
PremiumCompany Announcements
Astellas Wins EU Approval for Advanced Cancer Drug
2M ago
Bicycle says 45% of patients respond to bladder cancer drug, EN reports
PremiumThe Fly
Bicycle says 45% of patients respond to bladder cancer drug, EN reports
3M ago
MRK
PFE
See More ALPMF News >

Options Prices

Currently, No data available
---

Ownership Overview

7.46%83.34%
―
Insiders
7.46% Mutual Funds
― Other Institutional Investors
83.34% Public Companies and
Individual Investors
Detailed Ownership Overview >

4503 FAQ

What was Astellas Pharma Inc’s price range in the past 12 months?
Astellas Pharma Inc lowest stock price was ¥1426.00 and its highest was ¥1839.50 in the past 12 months.
    What is Astellas Pharma Inc’s market cap?
    Currently, no data Available
    When is Astellas Pharma Inc’s upcoming earnings report date?
    Astellas Pharma Inc’s upcoming earnings report date is Jan 30, 2025 which is in 64 days.
      How were Astellas Pharma Inc’s earnings last quarter?
      Astellas Pharma Inc released its earnings results on Oct 30, 2024. The company reported ¥20.06 earnings per share for the quarter, beating the consensus estimate of ¥18.013 by ¥2.047.
        Is Astellas Pharma Inc overvalued?
        According to Wall Street analysts Astellas Pharma Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Astellas Pharma Inc pay dividends?
          Astellas Pharma Inc pays a Annually dividend of ¥37 which represents an annual dividend yield of 4.73%. See more information on Astellas Pharma Inc dividends here
            What is Astellas Pharma Inc’s EPS estimate?
            Astellas Pharma Inc’s EPS estimate is ¥18.49.
              How many shares outstanding does Astellas Pharma Inc have?
              Astellas Pharma Inc has 1,809,663,100 shares outstanding.
                What happened to Astellas Pharma Inc’s price movement after its last earnings report?
                Astellas Pharma Inc reported an EPS of ¥20.06 in its last earnings report, beating expectations of ¥18.013. Following the earnings report the stock price went down -0.084%.
                  Which hedge fund is a major shareholder of Astellas Pharma Inc?
                  Currently, no hedge funds are holding shares in JP:4503
                  ---

                  Astellas Pharma Stock Smart Score

                  10
                  Unlock Smart Score
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Analyst Consensus

                  Moderate Buy
                  Average Price Target:
                  ¥1,950.55 (24.08% Upside)

                  Technicals

                  SMA
                  Positive
                  20 days / 200 days
                  Momentum
                  -10.13%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  3.28%
                  Trailing 12-Months
                  Asset Growth
                  1.95%
                  Trailing 12-Months
                  Top Smart Score Stocks >

                  Company Description

                  Astellas Pharma Inc

                  Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
                  ---

                  4503 Company Deck

                  ---

                  4503 Earnings Call

                  Q2 2024
                  0:00 / 0:00
                  ---

                  4503 Stock 12 Month Forecast

                  Average Price Target

                  ¥1,950.55
                  ▲(24.08% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1491":"¥1,491","2100":"¥2,100","1643.25":"¥1,643.3","1795.5":"¥1,795.5","1947.75":"¥1,947.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2099.999357064,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥2.10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1950.55152,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥1.95K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1749.99946422,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥1.75K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1491,1643.25,1795.5,1947.75,2100],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1805.9999505433846,1830.4999010867691,1854.999851630154,1879.4998021735385,1903.999752716923,1928.4997032603076,1952.9996538036924,1977.499604347077,2001.9995548904615,2026.499505433846,2050.999455977231,2075.499406520615,{"y":2099.999357064,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1794.5039630769231,1807.5079261538463,1820.5118892307692,1833.5158523076923,1846.5198153846154,1859.5237784615385,1872.5277415384614,1885.5317046153846,1898.5356676923077,1911.5396307692308,1924.5435938461537,1937.5475569230769,{"y":1950.55152,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1781.5,1779.076881863077,1776.6537637261538,1774.2306455892308,1771.8075274523076,1769.3844093153846,1766.9612911784616,1764.5381730415384,1762.1150549046154,1759.6919367676924,1757.2688186307691,1754.8457004938462,1752.422582356923,{"y":1749.99946422,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1731.063,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1615.595,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1621.344,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1604.575,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1605.679,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1492.175,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1515.169,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1554.309,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1621.334,"date":1720742400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1707.44,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1762.235,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1728,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1781.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Detailed Analyst Forecast >

                  Technical Analysis

                  Overall Consensus
                  Sell
                  7Bullish
                  1Neutral
                  14Bearish
                  Bullish
                  Neutral
                  Bearish
                  Overall Consensus
                  7
                  1
                  14
                  Technical Analysis
                  6
                  1
                  3
                  Moving Averages
                  1
                  0
                  11
                  Technical Analysis >
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  ALPMF
                  Astellas Pharma
                  ―
                  ―
                  TAK
                  Takeda Pharmaceutical Company
                  ―
                  ―
                  SNY
                  Sanofi
                  ―
                  ―
                  NVS
                  Novartis
                  ―
                  ―
                  BAYRY
                  Bayer
                  ―
                  ―
                  Compare JP:4503 Stocks >

                  Best Analysts Covering 4503

                  1 Year
                  Miki SogiBernstein
                  1 Year Success Rate
                  1/3 ratings generated profit
                  33%
                  1 Year Average Return
                  -5.23%
                  reiterated a buy rating 8 days ago
                  Copying Miki Sogi's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -5.23% per trade.
                  Best Analyst Covering >
                  Popular Stocks
                  ---

                  Become an Expert with TipRanks Premium

                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis
                  Subscribe NowSee Plans & Pricing